HyperCVAD is a commonly-used regimen for adults with newly-diagnosed acute lymphoblastic leukemia (ALL). However, relatively little is known about the application of minimal residual disease (MRD) detection with this treatment. To address this, we studied 142 adults with ALL treated with hyperCVAD over a 10-year period who had MRD assessed by either multi- Neg was significantly associated with EFS (P 5 .009), but not OS (P 5 .19), implying increasingly better EFS the earlier MRD Neg is achieved. These data add to our understanding of MRD assessment during treatment with hyperCVAD, aide clinicians with predicting relapse risk, and provide additional historical data on which future clinical trials can be designed.
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| I N TR ODU C TI ON
Minimal residual disease (MRD) is an established prognostic and predictive biomarker in acute lymphoblastic leukemia (ALL). 1 Its presence (MRD Pos ) or absence (MRD Neg ) at specific points during different treatment regimens can be used to risk-stratify patients, often with such impact that historical risk factors like white blood cell count (WBC) at diagnosis and cytogenetics are no longer important. [2] [3] [4] [5] [6] The prognostic impact of a rapid early response is also well described, though primarily in pediatric regimens. MRD Neg at the end of a 4-week induction and following consolidation in a pediatric regimen can be used to deintensify therapy on the basis of a very low risk of relapse. 7 Alternatively, MRD Pos despite 16 weeks of therapy is associated with a very high risk of subsequent relapse in adults. 8, 9 This risk can be ameliorated by allogeneic hematopoietic cell transplantation (HCT) while in morphologic remission. Therefore, not only is achieving MRD Neg critical to the success of ALL therapy, but also the time it takes to achieve this response is also important.
HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine) is among the most widely used regimens for adults with ALL. 10 It has proven to be an effective backbone for the addition of novel targeted agents, including ABL1 tyrosine kinase inhibi- 21 However, MFC data from other laboratories were included when utilized, the operating characteristics of which are not immediately available. For the purposes of this analysis, "quantifiably detectable" was defined as the presence of sufficient abnormal signal such that an unequivocal numerical result was given in the clinical report.
Results that were deemed by the interpreting pathologist to be "indeterminate," "below the threshold of enumeration," or the like were considered negative. Because of the high risk of morphologic relapse associated with recurrence of MRD, 22 relapse was defined as either morphologic (ie, > 5% bone marrow blasts) recurrence or MRD reappearance, 23 except when MRD reappearance occurred transiently within the first 3 months after HCT.
| Statistical analysis
Frequencies of characteristics between groups were compared using a two-tailed Fisher exact test. Kaplan-Meier curves estimated the probabilities of overall (OS) and event-free survival (EFS). Events were defined as morphologic or MRD reappearance, change in treatment due to inadequate response, death from any cause, or secondary malignancy. Frequencies of characteristics were compared between groups using a Fisher's exact test. Cox proportional hazards models were used to investigate associations between variables. Further, a test of proportional hazards was used to assess the impact of time on the association between MRD and both OS and EFS, in which MRD was modeled as a time-dependent covariate with left-truncation. Left-truncation was used to account for the varying times at which patients were first assessed for MRD. 24 The results of this assessment were used to generate a smoothed beta plot, where beta represents the log of the hazard of an event if MRD Neg is achieved with respect to the time at which MRD Neg is observed (ie, if beta < 0, then hazard is reduced).
| RE S U L TS

| Patient and treatment characteristics
From 241 adults with ALL treated at our center, we identified 144 (60%) that received hyperCVAD as their initial therapy. Two of these patients (1%) were excluded: 1 did not undergo any MRD assessments, and 1 had insufficient records available to know their outcome. The characteristics of the resulting 142 patients that comprised our study population are described in detail in the Supporting Information. The median age at diagnosis was 44 years (range 5 18-72). High-risk clinical features at diagnosis were observed as follows: 24% (n 5 34) had a high WBC; 48% (n 568) had high-risk cytogenetics, with the majority of these (71%, n 5 48) being Ph1; and 73% (n 5 103) were over age 35. All Ph1 pts received TKI with hyperCVAD: 23 (48%) received imatinib and 25 (52%) received dasatinib. Rituximab was added to hyper-CVAD in 25 patients (18%), 8 of whom (32%) were also Ph1 and received concomitant TKI. In 5 patients (4%), asparaginase was incorporated to augment the regimen in a manner similar to that described previously. 25 Front-line HCT (ie, following remission achieved with hyperCVAD) was performed in 65 patients (46%), approximately 2/3 of which were performed using myeloablative conditioning. Kaplan-Meier curves depicting OS and EFS for the entire cohort are shown in Figure   1 : 3-year OS was 65% and median OS was 5.6 years, while 3-year EFS was 60% and median EFS was 4.2 years. The median duration of follow-up for all surviving patients was 2.8 years (range: 0.4-9.9 years).
| Association between MRD and other factors
We then looked at the association between MRD and other factors likely to impact outcome in our cohort. We also sought to understand the prognostic impact that time to MRD Neg has in the context of hyperCVAD administration. As alluded to above, due to the varying times at which MRD was assessed in our cohort and the relative frequency at which patients achieved MRD Neg over time, traditional proportional hazards models or landmark analyses would not be appropriate. Using a nonproportional hazards test and adjusting for front-line HCT (here included as a time-dependent covariate), cytogenetics, and WBC, time to MRD Neg was highly significantly associated with EFS (P 5 .009), but not OS (P 5 .19).
The relationship between time to MRD Neg and EFS is depicted in 
| Role of MRD assessment by RT-PCR in Ph1 ALL
Since RT-PCR was only used for MRD assessments in Ph1 patients, we 
| D I SCUSSION
The incorporation of MRD monitoring into the treatment of ALL has become an accepted standard. 26 To date, however, its practical application into the commonly-used hyperCVAD regimen has been challenging due to the relative paucity of data available to guide such decisionmaking. Our analyses provide key new insights to help both practicing clinicians and clinical investigators better understand the role of MRD detection when using hyperCVAD, particularly as it relates to the general kinetics of response and the prognostic significance this holds.
One of the challenges in understanding the optimal timing of response assessment during hyperCVAD is its schedule of administration. Regimens with more canonical "Induction" and "Consolidation" of the first cycle) and at 3-month intervals thereafter. [15] [16] [17] 27 This approach allowed for more uniform interpretation across patients and provided more power for these specific times. However, it also potentially missed the impact of other times in between. Our data, while heterogeneous in this regard, provide a more diverse assessment, particularly at more intermediate points 1-2 months into treatment.
A particularly compelling aspect of our analysis is the clear timedependent nature of the prognostic impact of achieving MRD Neg during hyperCVAD. Our data suggest that the earlier MRD Neg is noted, the better the EFS will be. As a result, it is hard to define any specific inflection points at which prognosis clearly changes. If outcomes truly improve the earlier MRD Neg is achieved, an assessment around day 21
(ie, after the 1 st cycle) may identify a subset at the lowest risk of relapse. Considering that about half of patients in our cohort were alive and event-free beyond 3 years and 50% of patients who achieve MRD Neg did so within 68 days (ie, roughly after the 3 rd or 4 th cycle), this may act as a reasonable threshold to start considering a patient at particularly high risk of relapse. Further, MRD persistence beyond 120 days (ie, after the 6 th cycle) should raise serious concerns that MRD Neg will not be achieved at all and a change in treatment is warranted.
Again, our data are not able to clearly define such thresholds, nor are we able to comment on the appropriate strategies for patients with late clearance or overt persistence of MRD. These populations are clearly in need of continued investigation. It is also worth noting that this time-dependent relationship was not significantly linked to OS, though this may be ascribed to the relatively low number of survival events to include in the models (n 5 48) or the ability to effectively sal- 28 Lastly, as our study population is relatively small, we were limited in our ability to compare certain subgroups of interest. Patients with T-ALL may have achieved MRD Neg more rapidly and frequently, but the strength of this conclusion is tempered by that fact that only 6 such patients were assessed within 21
days and only about one-fifth of the study population had T-ALL.
Among those with B-ALL, patterns of response appeared similar between Ph-and Ph1, however.
In conclusion, not only is achievement of MRD Neg a key prognostic marker in adults receiving hyperCVAD for initial treatment of ALL, but the time to achieve MRD Neg is also an important consideration. Here, we have not only described in greater detail the general kinetics of response at the MRD level, but we have also shown that after adjusting for other factors known to impact outcome, earlier achievement of MRD Neg leads to a significant improvement in EFS. These data provide important guidance for the optimal management of adults receiving this regimen, suggesting that patients who are relatively late in achieving MRD Neg are less likely to do well and should be considered for alternative or investigational treatment strategies. Our results also provide insights to investigators seeking to improve upon historical results with front-line chemotherapy regimens for adults with ALL, particularly as MRD is poised to become an increasingly-utilized endpoint in clinical trials. 
